

? d s

Set	Items	Description
S1	0	S (T (3N) (REGULATORY (W) CELL)) (7N) (ISOLATE OR PURIFY OR ISOLATION OR PURIFICATION)
S2	307	S ((T (3N) (REGULATORY (W) CELL))OR T-CELL OR TREG) (7N) (ISOLATE OR PURIFY OR ISOLATION OR PURIFICATION)
S3	0	S S2 AND ((SORT OR PURIFY OR ENRICH) (7N) (CD25 OR ANTI-CD25))
S4	0	S S2 AND ((SORT OR PURIFY OR ENRICH) (S) (CD25 OR ANTI-CD25))
S5	39	S S2 AND ((CD25 OR ANTI-CD25))
S6	0	S S2 AND ((DEplete OR DEPLETION OR REMOVE) (S) (CD8 OR ANTI-CD8))
S7	17	S S2 AND ( (CD8 OR ANTI-CD8))
S8	3	S S5 AND ( (CD8 OR ANTI-CD8))
S9	3	RD (unique items)
S10	6	S ((SORT OR PURIFY OR ENRICH) (S) (CD25 OR ANTI-CD25)) AND ((DEplete OR DEPLETION OR REMOVE) (S) (CD8 OR ANTI-CD8))
S11	2	RD (unique items)
S12	11782	S ((CD25 OR ANTI-CD25) AND (CD8 OR ANTI-CD8))
S13	10462	S ((CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8))
S14	2	S S2 AND ((CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8))
S15	819	S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEPLETION OR REMOVE) AND (CD8 OR ANTI-CD8)AND (CD25 OR ANTI-CD25))
S16	0	S S2 AND S15
S17	709	S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEPLETION OR REMOVE) (S) ((CD8 OR ANTI-CD8)AND (CD25 OR ANTI-CD25)))
S18	614	S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEPLETION OR REMOVE) (S) ((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)))
S19	6	S S18 AND ((MICROBEAD OR BEAD OR DYNABEAD) (S) (CD8 OR ANTI-CD8))
S20	6	RD (unique items)
S21	1	S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEPLETION OR REMOVE) (S) (((CD8 OR ANTI-CD8) (7N) (MICROBEAD OR BEAD OR DYNABEAD)) (S) (CD25 OR ANTI-CD25)))
S22	6	S (SORT OR PURIFY OR ENRICH OR DEplete OR DEPLETION OR REMOVE) (S) (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (S) (MICROBEAD OR BEAD OR DYNABEAD))
S23	6	RD (unique items)
S24	24	S (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (S) (MICROBEAD OR BEAD OR DYNABEAD))
S25	17	RD (unique items)
S26	0	S S2 AND S25
S27	13	S S25 NOT PD>030417

?

[File 369] **New Scientist** 1994-2007/Nov W4  
(c) 2007 Reed Business Information Ltd. All rights reserved.

[File 370] **Science** 1996-1999/Jul W3  
(c) 1999 AAAS. All rights reserved.

*\*File 370: This file is closed (no updates). Use File 47 for more current information.*

[File 391] **Beilstein Reactions** 2007/Q1  
(c) 2007 Beilstein GmbH. All rights reserved.

[File 434] **SciSearch(R) Cited Ref Sci** 1974-1989/Dec  
(c) 2006 The Thomson Corp. All rights reserved.

[File 467] **ExtraMED(tm)** 2000/Dec  
(c) 2001 Informania Ltd. All rights reserved.

? s (t (3n) (regulatory (w) cell)) (7n) (isolate or purify or isolation or purification)

Processing

Processing

Processing

8625424 T  
1027788 REGULATORY  
14533837 CELL  
394312 ISOLATE  
34265 PURIFY  
1821231 ISOLATION  
1428055 PURIFICATION

S1 0 S (T (3N) (REGULATORY (W) CELL)) (7N) (ISOLATE OR PURIFY OR ISOLATION OR PURIFICATION)

? s ((T (3N) (REGULATORY (W) CELL))or T-cell or Treg) (7N) (ISOLATE OR PURIFY OR ISOLATION OR PURIFICATION)

Processing

Processing

8625424 T  
1027788 REGULATORY  
14533837 CELL  
914 T(3N)REGULATORY(W)CELL  
60424 T-CELL  
4515 TREG  
394312 ISOLATE  
34265 PURIFY  
1821231 ISOLATION  
1428055 PURIFICATION

S2 307 S ((T (3N) (REGULATORY (W) CELL))OR T-CELL OR TREG) (7N) (ISOLATE OR PURIFY OR ISOLATION OR PURIFICATION)

? s s2 and and ((sort or purify or enrich) (7n) (CD25 or anti-CD25))

>>>W: Operator "AND" in invalid position

>>>E: There is no result

? s s2 and ((sort or purify or enrich) (7n) (CD25 or anti-CD25))

307 S2

```

47189  SORT
34265  PURIFY
17153  ENRICH
38511  CD25
144    ANTI-CD25
39      ((SORT OR PURIFY) OR ENRICH) (7N) (CD25 OR ANTI-CD25)
S3      0  S S2 AND ((SORT OR PURIFY OR ENRICH) (7N) (CD25 OR ANTI-CD25))

? S S2 AND ((SORT OR PURIFY OR ENRICH) (s) (CD25 OR ANTI-CD25))
307    S2
47189  SORT
34265  PURIFY
17153  ENRICH
38511  CD25
144    ANTI-CD25
110    ((SORT OR PURIFY) OR ENRICH) (S) (CD25 OR ANTI-CD25)
S4      0  S S2 AND ((SORT OR PURIFY OR ENRICH) (S) (CD25 OR ANTI-CD25))

? S S2 AND ((CD25 OR ANTI-CD25))
307    S2
38511  CD25
144    ANTI-CD25
S5      39  S S2 AND ((CD25 OR ANTI-CD25))

? s s2 and ((deplete or depletion or remove) (s) (CD8 or anti-CD8))
307    S2
24280  DEplete
465841 DEpletion
219626 REMOVE
252684 CD8
106    ANTI-CD8
13701  ((DEplete OR DEpletion) OR REMOVE) (S) (CD8 OR ANTI-CD8)
S6      0  S S2 AND ((DEplete OR DEpletion OR REMOVE) (S) (CD8 OR ANTI-CD8))

? S S2 AND ( (CD8 OR ANTI-CD8))
307    S2
252684 CD8
106    ANTI-CD8
S7      17  S S2 AND ( (CD8 OR ANTI-CD8))

? S S5 AND ( (CD8 OR ANTI-CD8))
39      S5
252684 CD8
106    ANTI-CD8
S8      3  S S5 AND ( (CD8 OR ANTI-CD8))

? rd
>>>W: Duplicate detection is not supported for File 391.
Records from unsupported files will be retained in the RD set.
S9      3  RD (UNIQUE ITEMS)

? t s9/medium/all

```

9/3/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
 Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18838048 Biosis No.: 200600183443

**Isolation of human Treg for allogeneic transplantation: Evaluation of several cell sources.**

**Author:** Marks R (Reprint); Ibig-Rehm Y; Prinz G; Melchinger W; Finke J

**Author Address:** Univ Hosp Freiburg, Freiburg, Germany\*\*Germany

**Journal:** Blood 106 ( 11, Part 1 ): p 312A-313A NOV 16 2005 2005

**Conference/Meeting:** 47th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA  
December 10 -13, 2005; 20051210

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Poster

**Record Type:** Abstract

**Language:** English

9/3/2 (Item 1 from file: 34) [Links](#)

Fulltext available through: [ScienceDirect \(Elsevier\)](#) [USPTO Full Text Retrieval Options](#)  
SciSearch(R) Cited Ref Sci

(c) 2007 The Thomson Corp. All rights reserved.

02209557 Genuine Article#: KK671 No. References: 23

**ISOLATION AND CHARACTERIZATION OF A CDW50 NEGATIVE JURKAT T-CELL LINE VARIANT (PPL.1)**

**Author:** LOZANO F; PLACES L; ALBEROLAILA J; MILA M; VILLAMOR N; BARCELO J; FABREGAT V; VIVES J

**Corporate Source:** HOSP CLIN PROVINCIAL BARCELONA,SEREI IMMUNOL,VILLARROEL 170/E-08036 BARCELONA//SPAIN/; HOSP CLIN BARCELONA,SERV GENET/E-08036 BARCELONA//SPAIN/ ; HOSP CLIN BARCELONA,SERV HEMATOL/E-08036 BARCELONA//SPAIN/

**Journal:** LEUKEMIA RESEARCH, 1993, V 17, N1 ( JAN ), P 9-16

**ISSN:** 0145-2126

**Language:** ENGLISH **Document Type:** ARTICLE ( Abstract Available )

9/3/3 (Item 1 from file: 155) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
MEDLINE(R)

(c) format only 2007 Dialog. All rights reserved.

22203972 PMID: 16507266

[Isolation, identification and functional characterization of human CD4+ CD25+ Treg cells from human peripheral blood]

Yang Jiang-hua; Zhang Yong-xiang; Wang Fang; Yu Rong-bin; Su Chuan; Sun Nan-xiong  
Department of Infectious Diseases, the First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China. yjhpath@163.com

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology ( China ) Mar 2006 , 22 (2) p252-4, 257 , ISSN: 1007-8738--Print Journal Code: 101139110

Publishing Model Print

Document type: English Abstract; Journal Article

Languages: CHINESE

Main Citation Owner: NLM

Record type: In Process

? S ((SORT OR PURIFY OR ENRICH) (S) (CD25 OR ANTI-CD25)) and ((deplete or depletion or remove) (s) (CD8 or anti-CD8))

47189 SORT

34265 PURIFY

17153 ENRICH

38511 CD25

144 ANTI-CD25

110 ((SORT OR PURIFY) OR ENRICH) (S) (CD25 OR ANTI-CD25)

24280 DEplete

465841 DEPLETION

219626 REMOVE

252684 CD8

106 ANTI-CD8

13701 ((DEplete OR DEPLETION) OR REMOVE) (S) (CD8 OR ANTI-CD8)

S10 6 S ((SORT OR PURIFY OR ENRICH) (S) (CD25 OR ANTI-CD25)) AND ((DEplete OR DEPLETION OR REMOVE) (S) (CD8 OR ANTI-CD8))

? rd

>>>W: Duplicate detection is not supported for File 391.

Records from unsupported files will be retained in the RD set.

S11 2 RD (UNIQUE ITEMS)

? t s11/medium/all

11/3/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18573769 Biosis No.: 200510268269

**Depletion of in-vivo activated regulatory T cells followed by synchronized specific in-vitro activation allows the rapid isolation of leukemia-reactive T cells for immunotherapy**

**Author:** Jedema I (Reprint); Steeneveld E; Hoogendoorn M; Willmze R; Falkenburg J H F

**Author Address:** LUMC, Leiden, Netherlands\*\*Netherlands

**Journal:** Blood 104 ( 11, Part 1 ): p 88A-89A NOV 16 2004-2004

**Conference/Meeting:** 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA  
December 04 -07, 2004; 20041204

**Sponsor:** Amer Soc Hematol

ISSN: 0006-4971

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

11/3/2 (Item 2 from file: 5) Links

Fulltext available through: custom link USPTO Full Text Retrieval Options  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18484678 Biosis No.: 200510179178

**Large-scale depletion of CD25(+) regulatory T cells from patient leukapheresis samples**

**Author:** Powell Daniel J; Parker Linda L; Rosenberg Steven A (Reprint)

**Author Address:** NCI, Clin Res Ctr, Surg Branch, NIH, Room 3W-3940, 10 Ctr Dr, MSC 1201, Bethesda, MD 20892 USA\*\*USA

**Author E-mail Address:** sar@nih.gov

**Journal:** Journal of Immunotherapy 28 ( 4 ): p 403-411 JUL-AUG-2005.2005

**ISSN:** 1524-9557

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

? S ((CD25 OR ANTI-CD25) and (CD8 or anti-CD8))  
       38511 CD25  
       144 ANTI-CD25  
       252684 CD8  
       106 ANTI-CD8  
 S12 11782 S ((CD25 OR ANTI-CD25) AND (CD8 OR ANTI-CD8))

? S ((CD25 OR ANTI-CD25) (s) (CD8 OR ANTI-CD8))  
       38511 CD25  
       144 ANTI-CD25  
       252684 CD8  
       106 ANTI-CD8  
 S13 10462 S ((CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8))

? S s2 and ((CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8))  
       307 S2  
       38511 CD25  
       144 ANTI-CD25  
       252684 CD8  
       106 ANTI-CD8  
       10462 (CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8)  
 S14 2 S S2 AND ((CD25 OR ANTI-CD25) (S) (CD8 OR ANTI-CD8))

? t s14/meidum/all  
 >>>W: "MEIDUM" is not a valid format name in file(s): 5, 24, 28, 34-35, 40-41, 45, 50, 65, 71, 73, 91, 98, 110, 135-136, 143-144, 155, 164, 172, 185, 357, 369-370, 391, 434, 467

? t s14/medium/all

14/3/1 (Item 1 from file: 34) [Links](#)

Fulltext available through: [ScienceDirect \(Elsevier\)](#) [USPTO Full Text Retrieval Options](#)  
 SciSearch(R) Cited Ref Sci

(c) 2007 The Thomson Corp. All rights reserved.

02209557 **Genuine Article#:** KK671 **No. References:** 23

# **ISOLATION AND CHARACTERIZATION OF A CDW50 NEGATIVE JURKAT T-CELL LINE VARIANT (PPL.1)**

**Author:** LOZANO F; PLACES L; ALBEROLAILA J; MILA M; VILLAMOR N; BARCELO J; FABREGAT V; VIVES J

**Corporate Source:** HOSP CLIN PROVINCIAL BARCELONA,SEREI IMMUNOL,VILLARROEL 170/E-08036 BARCELONA//SPAIN/; HOSP CLIN BARCELONA,SERV GENET/E-08036 BARCELONA//SPAIN/ ; HOSP CLIN BARCELONA,SERV HEMATOL/E-08036 BARCELONA//SPAIN/

**Journal:** LEUKEMIA RESEARCH , 1993 , V 17 , N1 ( JAN ) , P 9-16

**ISSN:** 0145-2126

**Language:** ENGLISH **Document Type:** ARTICLE ( Abstract Available )

```

? S ((SORT OR PURIFY OR ENRICH or DEplete OR DEpletion OR REMOVE) and (CD8 OR
ANTI-CD8)and (CD25 OR ANTI-CD25))
    47189 SORT
    34265 PURIFY
    17153 ENRICH
    24280 DEplete
    465841 DEpletion
    219626 REMOVE
    252684 CD8
    106 ANTI-CD8
    38511 CD25
    144 ANTI-CD25
S15 819 S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) AND (CD8
OR ANTI-CD8)AND (CD25 OR ANTI-CD25))

? s s2 and s15
    307 S2
    819 S15
S16 0 S S2 AND S15

? S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (s) ((CD8 OR
ANTI-CD8)AND (CD25 OR ANTI-CD25)))
    47189 SORT
    34265 PURIFY
    17153 ENRICH
    24280 DEplete
    465841 DEpletion
    219626 REMOVE
    252684 CD8
    106 ANTI-CD8
    38511 CD25
    144 ANTI-CD25
S17 709 S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) ((CD8
OR ANTI-CD8)AND (CD25 OR ANTI-CD25)))

? S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) ((CD8 OR
ANTI-CD8)(s)(CD25 OR ANTI-CD25)))
    47189 SORT
    34265 PURIFY
    17153 ENRICH
    24280 DEplete
    465841 DEpletion
    219626 REMOVE
    252684 CD8
    106 ANTI-CD8
    38511 CD25
    144 ANTI-CD25
S18 614 S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) ((CD8
OR ANTI-CD8)(S)(CD25 OR ANTI-CD25)))

? s s18 and ((microbead or bead or dynabead)(s)(CD8 OR ANTI-CD8))
    614 S18
    1763 MICROBEAD
    47447 BEAD
    181 DYNABEAD
    252684 CD8
    106 ANTI-CD8
    587 ((MICROBEAD OR BEAD) OR DYNABEAD)(S)(CD8 OR ANTI-CD8)
S19 6 S S18 AND ((MICROBEAD OR BEAD OR DYNABEAD)(S)(CD8 OR ANTI-CD8))

```

? rd

>>>W: Duplicate detection is not supported for File 391.  
Records from unsupported files will be retained in the RD set.  
S20 6 RD (UNIQUE ITEMS)

? t s20/medium/all

20/3/1 (Item 1 from file: 5) Links

Fulltext available through: USPTO Full Text Retrieval Options

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18573124 Biosis No.: 200510267624

**A murine xenograft model for human T cell mediated graft versus host disease.**

**Author:** Nervi Bruno (Reprint); Rettig Michael; Ritchey Julie; Walker Jon; Bauer Gerhard; Herrbrich Phillip; Nolte Jan A; DiPersio John F

**Author Address:** Washington Univ, Sch Med, St Louis, MO 63130 USA\*\*USA

**Journal:** Blood 104 ( 11, Part 2 ): p 325B-326B NOV 16 2004 2004

**Conference/Meeting:** 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA  
December 04 -07, 2004; 20041204

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

20/3/2 (Item 2 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17793830 Biosis No.: 200400161171

**Generation of human CD4+CD25+ suppressor cell lines which markedly inhibit HLA mismatched dendritic cell stimulated MLR.**

**Author:** Godfrey Wayne R (Reprint); Spoden Darrin J (Reprint); Ge Ying (Reprint); Mortari Frank; Levine Bruce L; June Carl H; Blazar Bruce R (Reprint); Porter Stephen B (Reprint)

**Author Address:** Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN, USA\*\*USA

**Journal:** Blood 102 ( 11 ): p 947a November 16, 2003-2003

**Medium:** print

**Conference/Meeting:** 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA  
December 06-09, 2003; 20031206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract; Meeting Poster

**Record Type:** Abstract

**Language:** English

20/3/3 (Item 1 from file: 155) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
MEDLINE(R)

(c) format only 2007 Dialog. All rights reserved.

23131849 PMID: 17371959

**Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells.**

Hilchey Shannon P; De Asit; Rimsza Lisa M; Bankert Richard B; Bernstein Steven H  
James P. Wilmot Cancer Center.

Journal of immunology (Baltimore, Md. - 1950) ( United States ) Apr 1 2007 , 178 (7) p4051-61 , ISSN:  
0022-1767--Print Journal Code: 2985117R

Publishing Model Print

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: In Data Review

20/3/4 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rights reserved.

0396803 DBA Accession No.: 2006-10299 PATENT

**Isolating regulatory T cell from CD45RA+ blood cells, by contacting mononuclear cells isolated from umbilical cord blood, with antibody that binds CD25 to form mononuclear antibody complex, separating antibody cell population T-lymphocyte cell isolation via human culture umbilical cord cell for use in disease therapy**

**Author:** GODFREY W R; JUNE C

**Patent Assignee:** GODFREY W R; JUNE C 2006

**Patent Number:** US 20060062763 **Patent Date:** 20060323 **WPI Accession No.:** 2006-250694 ( 200626 )

**Priority Application Number:** US 226168 **Application Date:** 20050914

**National Application Number:** US 226168 **Application Date:** 20050914

**Language:** English

20/3/5 (Item 2 from file: 357) Links

Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rights reserved.

0284011 DBA Accession No.: 2002-05858 PATENT

**Restoration or enhancement of T-cell immune surveillance especially for treating an immune-compromised or immuno-suppressed animal, by infusion of peripheral blood lymphocytes, T-cells or activated T-cells T-lymphocyte or blood lymphocyte cell culture for use in immunotherapy**

**Author:** BERENSON R

**Patent Assignee:** XCYTE THERAPIES INC 2001

**Patent Number:** WO 200189539 **Patent Date:** 20011129 **WPI Accession No.:** 2002-075346 ( 200210 )

**Priority Application Number:** US 207120 **Application Date:** 20000525

**National Application Number:** WO 2001US17218 **Application Date:** 20010524

**Language:** English

20/3/6 (Item 1 from file: 370) [Links](#)

Science

(c) 1999 AAAS. All rights reserved.

00504336 (USE 9 FOR FULLTEXT)

**Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy**

Finzi, Diana; Hermankova, Monika; Pierson, Theodore; Carruth, Lucy M.; Buck, Christopher; Chaisson, Richard E.; Quinn, Thomas C.; Chadwick, Karen; Margolick, Joseph; Brookmeyer, Ronald; Gallant, Joel; Markowitz, Martin; Ho, David D.; Richman, Douglas D.; Siliciano, Robert F.

D. Finzi, M. Hermankova, T. Pierson, L. M. Carruth, C. Buck, R. E. Chaisson, T. C. Quinn, J. Gallant, R. F. Siliciano, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. ; K. Chadwick and J. Margolick, Department of Molecular Microbiology and Immunology, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205, USA. ; R. Brookmeyer, Department of Biostatistics, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205, USA. ; M. Markowitz and D. D. Ho, Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY 10016, USA. ; D. D. Richman, Departments of Medicine and Pathology, University of California San Diego, La Jolla CA 92093, USA.

Science Vol. 278 5341 pp. 1295

**Publication Date:** 11-14-1997 ( 971114 ) **Publication Year:** 1997

**Document Type:** Journal **ISSN:** 0036-8075

**Language:** English

**Section Heading:** Reports

**Word Count:** 4941

? t s20/full1/1,2

20/9/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18573124 Biosis No.: 200510267624

**A murine xenograft model for human T cell mediated graft versus host disease.**

**Author:** Nervi Bruno (Reprint); Rettig Michael; Ritchey Julie; Walker Jon; Bauer Gerhard; Herrbrich Phillip; Nolte Jan A; DiPersio John F

**Author Address:** Washington Univ, Sch Med, St Louis, MO 63130 USA\*\*USA

**Journal:** Blood 104 ( 11, Part 2 ): p 325B-326B NOV 16 2004 2004

**Conference/Meeting:** 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA  
December 04 -07, 2004; 20041204

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

**Abstract:** Murine xenograft models of human T cell (HuT) mediated graft-versus-host-disease (GvHD) are of potential value but limited by poor engraftment and low and variable incidence of clinical GvHD even after injection of  $> 10(8)$  HuT cells. The NOD SCID beta 2M null mice (beta 2 mice) lack macrophage activity, T, B and NK cells and represent an improved target for HuT cell expansion and activation compared to other immunodeficient mouse models. To induce GvHD, sublethally irradiated beta 2 mice were injected intravenously via the tail vein (iv) or retroorbitally (to) with human peripheral blood mononuclear cells (huPBMC) or purified HuT (98% purity). beta 2 mice conditioned with 250cGy and injected iv with huPBMC ( $10(7)$  T cells;  $n=4$ ) or HuT ( $0.5-2 \times 10(7)$  T cells;  $n=28$ ) failed to engraft and did not develop GvHD. In contrast, beta 2 mice conditioned with 250cGy and injected to with huPBMC ( $10(7)$  T cells;  $n=11$ ) or HuT cells ( $10(7)$ ;  $n=14$ ) exhibited 19% HuT engraftment 2-3 weeks post-infusion and developed weight loss ( $> 20\%$ ) consistent with lethal GvHD, with an overall survival of 82% and 21%, respectively, at 5 weeks ( $p=0.006$ ). Addition of IL-2 ( $3 \times 10(5)$  IU IP/TIW) had no effect on T cell expansion or GvHD. FACS analysis demonstrated HuT infiltration in the spleen (46%), liver (60%), lung (49%), kidney (40%), and bone marrow (11%). Histological analysis showed an extensive and diffuse accumulation of immature lymphocytes in the spleen, thymus and lymph nodes, and a perivascular infiltration in the lung, liver, kidney but not in the skin or gut. The immunohistochemistry confirmed that these cells were HuT (human CD45+ and CD3+). Furthermore, we observed a 10-15 fold increase in the expression of T cell activation markers CD25, CD30, and CD69 in both the peripheral blood and tissues, compared with naive T cells or T cells from mice that did not develop GvHD. We also evaluated the levels of various human cytokines in the serum of the beta 2 mice using a cytometric bead array multiplex assay. On day 10 after the injection of HuT and before the start of any clinical sign of GvHD, mice that went on to develop lethal GvHD had 90 times higher levels of IFN gamma in serum ( $> 5000$  pg/ml) compared to mice that did not develop GvHD ( $< 62$  pg/ml) ( $p=0.003$ ). Interestingly both had nearly identical numbers of HuT/ul in blood ( $32 \pm 39$  and  $33 \pm 41$  HuT/ul) on day 10. We also observed a significant increase in human IL-10 levels and TNF alpha in mice that developed GvHD. Mice that developed lethal GvHD had a 70 fold increase of HuT/ul in the 3(rd) week (1550 versus 22/ul  $P < 0.003$ ). We improved this model by depletion of murine macrophages using clodronate-containing liposomes (clod) administered iv before the HuT injections. Mice injected with  $5 \times 10(6)$  HuT with clod developed lethal GvHD (3/3) on day 15.7  $\pm$  1.5, with  $10(7)$  HuT (3/3)

on day 10.3 +/- 5.4 and mice injected with 10(7)HuT without clod on day 13.4+5.4 (8/12)(p < 0.05). In contrast, RAG2 gamma-/- mice (RAG2) treated in identical fashion to the beta2 mice failed to engraft HuT after both iv and to injection (350cGy). Both increasing radiation doses (350 to 600cGy) and/or the addition of clod iv resulted in significantly enhanced engraftment of HuT and lethal GvHD. CD4/ CD8 ratio of HuT cells expanding in RAG2 mice was < 1 in sharp contrast to the 02 micewhere the ratio was > 2.5. Conclusion: NOD-SCID-beta 2M null xenotransplant model is uniquely permissive for human T cell expansion after sublethal radiation and may be used as a preclinical platform to study the impact of ex-vivo manipulation. and genetic modification of human T cell as GvHD.

**Descriptors:**

**Major Concepts:** Methods and Techniques; Blood and Lymphatics--Transport and Circulation; Immune System--Chemical Coordination and Homeostasis

**Biosystematic Names:** Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae-- Rodentia, Mammalia, Vertebrata, Chordata, Animalia

**Organisms:** human (Hominidae); murine (Muridae)

**Organisms: Parts Etc:** T cell--immune system, blood and lymphatics; peripheral blood mononuclear cell {PBMC}--immune system, blood and lymphatics

**Common Taxonomic Terms:** Humans; Primates; Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Rodents; Vertebrates

**Diseases:** graft-versus-host disease {GvHD}--immune system disease

**Mesh Terms:** Graft vs Host Disease (MeSH)

**Chemicals & Biochemicals:** CD3; CD45; CD69; CD30; CD25

**Concept Codes:**

00520 General biology - Symposia, transactions and proceedings

02506 Cytology - Animal

02508 Cytology - Human

10064 Biochemistry studies - Proteins, peptides and amino acids

15002 Blood - Blood and lymph studies

15004 Blood - Blood cell studies

34502 Immunology - General and methods

34508 Immunology - Immunopathology, tissue immunology

**Biosystematic Codes:**

86215 Hominidae

86375 Muridae

20/9/2 (Item 2 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17793830 Biosis No.: 200400161171

**Generation of human CD4+CD25+ suppressor cell lines which markedly inhibit HLA mismatched dendritic cell stimulated MLR.**

**Author:** Godfrey Wayne R (Reprint); Spoden Darrin J (Reprint); Ge Ying (Reprint); Mortari Frank; Levine Bruce L; June Carl H; Blazar Bruce R (Reprint); Porter Stephen B (Reprint)

**Author Address:** Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN, USA\*\*USA

**Journal:** Blood 102 ( 11 ): p 947a November 16, 2003 2003

**Medium:** print

**Conference/Meeting:** 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA  
December 06-09, 2003; 20031206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract; Meeting Poster

**Record Type:** Abstract

**Language:** English

**Abstract:** CD4+CD25+ suppressor cells have been shown to mediate self and allograft tolerance in multiple mouse models. These cells have also been shown to prevent GVHD, while possibly still allowing for anti-tumor GVL effects. Studies of this cell type in humans have been restricted by the small number present in peripheral blood, overlapping CD25 dim cells, and their naturally anergic or hypoproliferative state. To date studies with human CD4+CD25+ cells have revealed only modest suppressive function, and limited expansion capability. Therefore, we sought to determine methods for improved isolation, expansion, and activation of these cells, in order to characterize their suppressive function. We found that stringent magnetic microbead anti- CD25 based purification, in combination with CD8, CD14, CD19, and CD56 lineage depletion was required for stable suppressive cell line generation. In addition, culture with cell sized dynabeads coated with anti-CD3/anti-CD28, irradiated CD4+ feeder cells, and IL2 were required for optimal expansion. With these methods, we have developed an approach yielding 100X expansion in cell number after 3-4 weeks culture from normal donors. Short term suppressor cell lines can be generated from most donors which potently suppress DC driven HLA mismatched allo-MLR (>95% inhibition). The suppressive effect remains pronounced even when titrated out to a 1/10 suppressor/responder cell ratio. Importantly, these cultured suppressors can impair activated and matured DC driven allogeneic responses with equivalent efficiency. The mechanism appears contact dependent, as the suppressive effect is abrogated by transwell membranes (1 micron pore), and neutralizing antibodies to immunosuppressive cytokines IL10, IL10R, or TGF beta, or combinations thereof do not reverse suppression. The suppressor cells potently impair cytokine production, as accumulation of IL2, IFN-gamma, TNF-alpha, and GM-CSF in the MLR supernatant is prevented. Antibodies to negative signaling molecules CTLA4, PD-1, PDL-1, fasL, and TRAIL did not interfere with suppression. In contrast to murine studies, anti-GITR did not affect suppressor function. Interestingly, an agonist antibody to OX40 (CD134) partially reversed suppression. These results demonstrate that moderate scale expansion of suppressor cells is possible, provided the CD4+CD25+ cells are stringently purified, hyperactivated, and supplemented with appropriate feeder cells. The expanded cells exhibit augmented suppressive function on a per cell basis compared to fresh CD4+CD25+ cells. The routine availability of suppressor cell lines will facilitate the study of the basic biology of these cells. In addition, we have now adapted the methods for large scale GMP purification and culture for pilot

testing in BMT patients. These cultured suppressor cells may be useful in clinical trials evaluating a novel form of immunosuppressive therapy.

**Registry Numbers:** 83869-56-1: GM-CSF

**Descriptors:**

**Major Concepts:** Blood and Lymphatics--Transport and Circulation; Immune System--Chemical Coordination and Homeostasis; Methods and Techniques

**Biosystematic Names:** Hominidae--Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae-- Rodentia, Mammalia, Vertebrata, Chordata, Animalia

**Organisms:** human (Hominidae); murine (Muridae)

**Organisms: Parts Etc:** dendritic cell--immune system

**Common Taxonomic Terms:** Humans; Primates; Animals; Chordates; Mammals; Nonhuman Vertebrates; Nonhuman Mammals; Rodents; Vertebrates

**Chemicals & Biochemicals:** CD14; CD19; CD28; CD4; CD56; CD8; CTLA4; GM-CSF {granulocyte-macrophage colony stimulating factor}; IFN-gamma {interferon-gamma}; IL-10 {interleukin-10}; IL-10R {interleukin-10 receptor}; IL-2 {interleukin-2}; PD-1; PDL-1; TGF-beta {transforming growth factor-beta}; TNF-alpha {tumor necrosis factor-alpha}; TRAIL {tumor necrosis factor-related apoptosis-inducing ligand}; fasL {fas ligand}

**Methods & Equipment:** HLA matching--laboratory techniques

**Miscellaneous Terms:** human CD4-positive CD25-positive suppressor T cell line; Meeting Abstract; Meeting Poster

**Concept Codes:**

00520 General biology - Symposia, transactions and proceedings

02506 Cytology - Animal

02508 Cytology - Human

10064 Biochemistry studies - Proteins, peptides and amino acids

15002 Blood - Blood and lymph studies

15004 Blood - Blood cell studies

17002 Endocrine - General

34502 Immunology - General and methods

**Biosystematic Codes:**

86215 Hominidae

86375 Muridae

? S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) (((CD8 OR ANTI-CD8) (7n) (MICROBEAD OR BEAD OR DYNABEAD)) (S) (CD25 OR ANTI-CD25)))

47189 SORT  
34265 PURIFY  
17153 ENRICH  
24280 DEplete  
465841 DEpletion  
219626 REMOVE  
252684 CD8  
106 ANTI-CD8  
1763 MICROBEAD  
47447 BEAD  
181 DYNABEAD  
38511 CD25  
144 ANTI-CD25

S21 1 S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) (((CD8 OR ANTI-CD8) (7N) (MICROBEAD OR BEAD OR DYNABEAD)) (S) (CD25 OR ANTI-CD25)))

? t s21/medium

21/3/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17793830 Biosis No.: 200400161171

**Generation of human CD4+CD25+ suppressor cell lines which markedly inhibit HLA mismatched dendritic cell stimulated MLR.**

**Author:** Godfrey Wayne R (Reprint); Spoden Darrin J (Reprint); Ge Ying (Reprint); Mortari Frank; Levine Bruce L; June Carl H; Blazar Bruce R (Reprint); Porter Stephen B (Reprint)

**Author Address:** Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN, USA\*\*USA

**Journal:** Blood 102 ( 11 ): p 947a November 16, 2003 2003

**Medium:** print

**Conference/Meeting:** 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA  
December 06-09, 2003; 20031206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract; Meeting Poster

**Record Type:** Abstract

**Language:** English

? S ((SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (s) (MICROBEAD OR BEAD OR DYNABEAD))

>>>W: Unmatched parentheses

>>>E: There is no result

? S (SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (s) (MICROBEAD OR BEAD OR DYNABEAD))

47189 SORT  
34265 PURIFY  
17153 ENRICH  
24280 DEplete  
465841 DEpletion  
219626 REMOVE  
252684 CD8  
106 ANTI-CD8  
38511 CD25  
144 ANTI-CD25  
1763 MICROBEAD  
47447 BEAD  
181 DYNABEAD

S22 6 S (SORT OR PURIFY OR ENRICH OR DEplete OR DEpletion OR REMOVE) (S) (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (S) (MICROBEAD OR BEAD OR DYNABEAD))

? rd

>>>W: Duplicate detection is not supported for File 391.

Records from unsupported files will be retained in the RD set.

S23 6 RD (UNIQUE ITEMS)

? s (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (S) (MICROBEAD OR BEAD OR DYNABEAD))

252684 CD8  
106 ANTI-CD8  
38511 CD25  
144 ANTI-CD25  
1763 MICROBEAD  
47447 BEAD  
181 DYNABEAD

S24 24 S (((CD8 OR ANTI-CD8) (S) (CD25 OR ANTI-CD25)) (S) (MICROBEAD OR BEAD OR DYNABEAD))

?

? rd

>>>W: Duplicate detection is not supported for File 391.

Records from unsupported files will be retained in the RD set.

S25 17 RD (UNIQUE ITEMS)

? s s2 and s25

307 S2  
17 S25

S26 0 S S2 AND S25

? s s25 not pd>030417

Processing

>>>W: One or more prefixes are unsupported  
or undefined in one or more files.

17 S25  
11402525 PD>030417

S27 13 S S25 NOT PD>030417

? t s27/medium/all

27/3/1 (Item 1 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

0019454765 Biosis No.: 200700114506

**Functional adaptive CD4 Foxp3 T cells develop in MHC class II-deficient mice**

**Author:** Bochtler Petra; Wahl Christian; Schirmbeck Reinhold; Reimann Joerg (Reprint)

**Author Address:** Univ Ulm, Dept Internal Med 1, Albert Einstein Allee 11, D-89081 Ulm, Germany\*\*Germany

**Author E-mail Address:** joerg.reimann@uni-ulm.de

**Journal:** Journal of Immunology 177 ( 12 ): p 8307-8314 DEC 15 2006 2006

**ISSN:** 0022-1767

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

27/3/2 (Item 2 from file: 5) Links

Fulltext available through: USPTO Full Text Retrieval Options

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18838282 Biosis No.: 200600183677

**CD4(+)CD25(+) T cells can inhibit CD8 T cell mediated GVHD: Requirement for in vivo recognition of allogeneic host MHC class II antigens.**

**Author:** Levy Robert B (Reprint); Jones Angela

**Author Address:** Univ Miami, Miller Sch Med, Miami, FL 33152 USA\*\*USA

**Journal:** Blood 106 ( 11, Part 1 ): p 380A NOV 16 2005 2005

**Conference/Meeting:** 47th Annual Meeting of the American-Society-of-Hematology Atlanta, GA, USA  
December 10 -13, 2005; 20051210

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

27/3/3 (Item 3 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18738191 Biosis No.: 200600083586

**Differential role of T cell subsets in generating ileitis in TNF delta are mice**

**Author:** Staples Matthew I; Rivera-Nieves Jesus; Ross William; Kennedy Sarah B; Reuter Brian K; Cominelli Fabio; Pizarro Theresa T

**Journal:** Gastroenterology 126 ( 4, Suppl. 2 ): p A119 APR 2004 2004

**Conference/Meeting:** Digestive Disease Week/105th Annual Meeting of the  
American-Gastroenterological-Association New Orleans, LA, USA May 16 -20, 2004; 20040516

**Sponsor:** Amer Gastroenterol Assoc

**ISSN:** 0016-5085

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

27/3/4 (Item 4 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18575604 Biosis No.: 200510270104

**Comparison of the division rate and proliferative capacity of naive and ex vivo activated T cells after allogeneic bone marrow transplantation.**

**Author:** Rettig Michael P (Reprint); Ritchey Julie K; Nervi Bruno; Bonyhadi Mark L; DiPersio John F

**Author Address:** Washington Univ, Sch Med, Div Oncol, Siteman Canc Ctr, St Louis, MO USA\*\* USA

**Journal:** Blood 104 ( 11, Part 1 ): p 587A NOV 16 2004 2004

**Conference/Meeting:** 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA

December 04 -07, 2004; 20041204

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Poster

**Record Type:** Abstract

**Language:** English

27/3/5 (Item 5 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18573124 Biosis No.: 200510267624

**A murine xenograft model for human T cell mediated graft versus host disease.**

**Author:** Nervi Bruno (Reprint); Rettig Michael; Ritchey Julie; Walker Jon; Bauer Gerhard; Herrbrich Phillip; Nolte Jan A; DiPersio John F

**Author Address:** Washington Univ, Sch Med, St Louis, MO 63130 USA\*\*USA

**Journal:** Blood 104 ( 11, Part 2 ): p 325B-326B NOV 16 2004 2004

**Conference/Meeting:** 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA  
December 04 -07, 2004; 20041204

**Sponsor:** Amer Soc Hematol

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract

**Record Type:** Abstract

**Language:** English

27/3/6 (Item 6 from file: 5) [Links](#)

Fulltext available through: [Ebsco Host EJS \(Electronic Journals Service\)](#) [USPTO Full Text Retrieval Options](#)  
[Blackwell Publishing](#)

Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

18376683 Biosis No.: 200510071183

**Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)/CD25(-) cells promote systemic alopecia areata and CD4(+)/CD25(+) cells blockade disease onset in the C3H/HeJ mouse model**

**Author:** McElwee Kevin J (Reprint); Freyschmidt-Paul Pia; Hoffmann Rolf; Kissling Sabine; Hummel Susanne; Vitacolonna Mario; Zoeller Margot

**Author Address:** Univ British Columbia, Div Dermatol, 835 W 10th Ave, Vancouver, BC, Canada \*\*Canada

**Author E-mail Address:** kevin@keratin.com

**Journal:** Journal of Investigative Dermatology 124 ( 5 ): p 947-957 MAY 05 2005

**ISSN:** 0022-202X

**Document Type:** Article

**Record Type:** Abstract

**Language:** English

27/3/7 (Item 7 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17793830 ·Biosis No.: 200400161171

**Generation of human CD4+CD25+ suppressor cell lines which markedly inhibit HLA mismatched dendritic cell stimulated MLR.**

**Author:** Godfrey Wayne R (Reprint); Spoden Darrin J (Reprint); Ge Ying (Reprint); Mortari Frank; Levine Bruce L; June Carl H; Blazar Bruce R (Reprint); Porter Stephen B (Reprint)

**Author Address:** Department of Pediatrics, University of Minnesota Cancer Center, Minneapolis, MN, USA\*\*USA

**Journal:** Blood 102 ( 11 ): p 947a November 16, 2003 2003

**Medium:** print

**Conference/Meeting:** 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA  
December 06-09, 2003; 20031206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract; Meeting Poster

**Record Type:** Abstract

**Language:** English

27/3/8 (Item 8 from file: 5) Links

Fulltext available through: USPTO Full Text Retrieval Options  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17780587 Biosis No.: 200400147248

**Differential localization and function of ARF6 in anergic T cells: A candidate marker for their phenotypic identification.**

**Author:** Tzachanis Dimitrios (Reprint); Appleman Leonard J (Reprint); van Puijenbroek Anrde A A F L (Reprint); Berezovskaya Alla (Reprint); Nadler Lee M (Reprint); Boussiotis Vassiliki A (Reprint)

**Author Address:** Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA\*\*USA

**Journal:** Blood 102 ( 11 ): p 526a November 16, 2003 2003

**Medium:** print

**Conference/Meeting:** 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA  
December 06-09, 2003; 20031206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Abstract; Meeting Poster

**Record Type:** Abstract

**Language:** English

27/3/9 (Item 9 from file: 5) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
Biosis Previews(R)

(c) 2007 The Thomson Corporation. All rights reserved.

17379409 Biosis No.: 200300336152

**Dendritic Cells (DCs) Pulsed with NY-ESO-1 and MAGE-3 Peptides Stimulate Myeloma  
Cytotoxic-T-Lymphocytes (CTLs).**

**Author:** Szmania Susann M (Reprint); Bennett Grant (Reprint); Batchu Ramesh B (Reprint); Rosen Nancy A (Reprint); Gupta Sushil K (Reprint); Xie J (Reprint); Cottler-Fox Michele (Reprint); Barlogie Bart (Reprint); Tricot Guido (Reprint); Yi Qing (Reprint); Rhee Frits van (Reprint)

**Author Address:** Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR, USA\*\*USA

**Journal:** Blood 100 ( 11 ): p Abstract No. 1552 November 16, 2002 2002

**Medium:** print

**Conference/Meeting:** 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA  
December 06-10, 2002; 20021206

**Sponsor:** American Society of Hematology

**ISSN:** 0006-4971

**Document Type:** Meeting; Meeting Poster; Meeting Abstract

**Record Type:** Abstract

**Language:** English

27/3/10 (Item 1 from file: 155) [Links](#)

Fulltext available through: [USPTO Full Text Retrieval Options](#)  
MEDLINE(R)

(c) format only 2007 Dialog. All rights reserved.

23131849 PMID: 17371959

**Follicular Lymphoma Intratumoral CD4+CD25+GITR+ Regulatory T Cells Potently Suppress CD3/CD28-Costimulated Autologous and Allogeneic CD8+CD25- and CD4+CD25- T Cells.**

Hilchey Shannon P; De Asit; Rimsza Lisa M; Bankert Richard B; Bernstein Steven H  
James P. Wilmot Cancer Center.

Journal of immunology (Baltimore, Md. - 1950) ( United States ) Apr 1 2007 , 178 (7) p4051-61 , ISSN:  
0022-1767--Print Journal Code: 2985117R

Publishing Model Print

**Document type:** Journal Article

**Languages:** ENGLISH

**Main Citation Owner:** NLM

**Record type:** In Data Review

27/3/11 (Item 1 from file: 357) Links

Derwent Biotech Res.

(c) 2007 The Thomson Corp. All rights reserved.

0308981 DBA Accession No.: 2003-10766 PATENT

**New immortalized CD4+CD25+ regulatory cells regulating immune tolerance, useful in preventing or controlling undesirable immune reactions, such as transplant rejection, autoimmune diseases, allergic and asthmatic reaction vector expression in cell culture for use in immunotherapy**

**Author:** FIELD E H; HAXHINASTO S; FEHR T

**Patent Assignee:** UNIV IOWA RES FOUND 2003

**Patent Number:** WO 2003008558 **Patent Date:** 20030130 **WPI Accession No.:** 2003-239328 ( 200323 )

**Priority Application Number:** US 307000 **Application Date:** 20010720

**National Application Number:** WO 2002US23161 **Application Date:** 20020719

**Language:** English